Craft
  • Home
  •  / Portola Pharmaceuticals
Portola Pharmaceuticals

Portola Pharmaceuticals

Revenue

$116.6 M

FY, 2019

Market Capitalization

$1.4 B

2020-07-06

Portola Pharmaceuticals Summary

Company summary

Overview
Portola Pharmaceuticals is a biopharmaceutical company. It develops therapies to treat thrombosis and other hematologic diseases. Portola is dedicated to the discovery and development of medicines for patients with thrombosis and hematologic cancers. The Company provides two medicines: Andexxa and Bevyxxa.
Type
Public
Founded
2003
HQ
South San Francisco, CA, US | view all locations
Website
https://www.portola.com
Cybersecurity rating
ESG rating
out of 100 | View all ESG data
Sectors

Key people

  • Scott Garland

    Scott Garland, President and Chief Executive Officer, Director

    • Mardi C. Dier

      Mardi C. Dier, Executive Vice President, Chief Financial Officer and Chief Business Officer

      • Sheldon Koenig

        Sheldon Koenig, Executive Vice President, Chief Commercial Officer

        • Ernie Meyer

          Ernie Meyer, Executive Vice President, Chief Human Resources Officer

          LocationsView all

          3 locations detected

          • South San Francisco, CA HQ

            United States

            270 E Grand Ave

          • Planegg, BY

            Germany

            Fraunhoferstraße 12

          • Amsterdam, NH

            Netherlands

            Prins Bernhardplein 200

          Portola Pharmaceuticals Financials

          Summary financials

          Revenue (Q1, 2020)
          $26.4M
          Gross profit (Q1, 2020)
          $22.1M
          Net income (Q1, 2020)
          ($68.8M)
          Cash (Q1, 2020)
          $196.2M
          EBIT (Q1, 2020)
          ($58.4M)
          Enterprise value
          $1.4B

          Footer menu